Treatment with teclistamab, administered subcutaneously at a dose of 1500 µg/kg once weekly, led to a high response rate and an encouraging safety profile in patients with relapsed/refractory multiple myeloma.
Recent Content
- Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab
- Pancreatic cancer growth tied to cells’ self-eating process
- Telix seeks European approval of glioma imaging agent
- Impact of frailty on infection risk in non-transplant eligible multiple myeloma patients: a systematic review and meta-analysis
- (no title)
- (no title)
- Elenagen helps women with ovarian cancer live 1 year longer
- (no title)
- Blood test helps predict myeloma relapse risk without biopsy
- The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D